ArticleInvestigative ophthalmology & visual science2026
Steroidome Dysregulation and Complement C4 Copy Number Variation in Men With Central Serous Chorioretinopathy.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Central serous chorioretinopathy (CSCR) is a retinal disease predominantly affecting middle-aged men, in which systemic glucocorticoid exposure is a well-established risk factor. Genetic studies have implicated copy number variation (CNV) in complement component 4 (C4), located within the RCCX module alongside the steroid 21-hydroxylase gene (CYP21A2), in modifying disease susceptibility. However, the relationship between adrenal steroid metabolism and C4 CNV in CSCR has not been investigated. Methods: We analyzed the serum steroidome of 45 male patients with CSCR and 49 age-matched healthy male controls using liquid chromatography-tandem mass spectrometry (LC-MS/MS). In a subset of 20 patients with complex CSCR, genomic C4A and C4B copy numbers were quantified by qPCR and correlated with circulating steroid metabolites, including indices of CYP21A2 activity. Results: Patients with CSCR exhibited significant alterations in steroid metabolism compared with controls. In the glucocorticoid pathway, 17-hydroxyprogesterone (17-OHP) was elevated, cortisone was reduced, and the 11-deoxycortisol/17-OHP ratio, reflecting CYP21A2 activity, was significantly lower. In the mineralocorticoid pathway, 11-deoxycorticosterone, dehydrocorticosterone, and aldosterone were decreased, whereas in the androgen pathway dehydroepiandrosterone (DHEA) was increased. In the subgroup with genomic analysis, patients carrying only one C4B copy displayed reduced CYP21A2 activity, as reflected by a lower S/17-OHP ratio, and correlations were observed among C4 copy number, 17-OHP levels, and the S/17-OHP ratio. Conclusions: Men with CSCR present systemic dysregulation of glucocorticoid, mineralocorticoid, and androgen pathways, linked to impaired CYP21A2 activity. The possible correlation between low C4B copy number and altered steroid metabolism could suggest a role of the RCCX module in CSCR susceptibility, warranting further genetic and functional investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.